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Abstract
Background: Ganoderma lucidum has been widely used as a herbal medicine for promoting health
and longevity in China and other Asian countries. Polysaccharide extracts from Ganoderma lucidum
have been reported to exhibit immuno-modulating and anti-tumor activities. In previous studies,
F3, the active component of the polysaccharide extract, was found to activate various cytokines
such as IL-1, IL-6, IL-12, and TNF-α. This gave rise to our investigation on how F3 stimulates
immuno-modulating or anti-tumor effects in human leukemia THP-1 cells.
Results: Here, we integrated time-course DNA microarray analysis, quantitative PCR assays, and
bioinformatics methods to study the F3-induced effects in THP-1 cells. Significantly disturbed
pathways induced by F3 were identified with statistical analysis on microarray data. The apoptosis
induction through the DR3 and DR4/5 death receptors was found to be one of the most significant
pathways and play a key role in THP-1 cells after F3 treatment. Based on time-course gene
expression measurements of the identified pathway, we reconstructed a plausible regulatory
network of the involved genes using reverse-engineering computational approach.
Conclusion: Our results showed that F3 may induce death receptor ligands to initiate signaling via
receptor oligomerization, recruitment of specialized adaptor proteins and activation of caspase
cascades.
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Background
Ganoderma lucidum (G. lucidum, Reishi or Ling-Zhi) has
been used in traditional Chinese medicine as an anti-
tumor medication or as an immuno-modulator. Many
reports showed Reishi extracts to possess anti-proliferative
effects on many cancers, such as acute myelogenous
leukemia [1], lung cancer [2], breast cancer [3], colorectal
cancer [4], bladder cancer [5] and prostate cancer [6,7]. A
fucose-containing polysaccharide fraction (F3), isolated
from the water-soluble Reishi extract, is able to stimulate
spleen cell proliferation and cytokine expression [8-11].
Understanding how the molecular mechanism is respon-
sible for the effects of F3 on cancer cells remains to be elu-
cidated and will require whole-system approaches, since
isolated single molecular studies have not, so far, been
able to unlock cancer-system complexity. Microarray anal-
ysis is the first step in understanding integrated cell func-
tions and cell-specific gene-expression profiles. The
response of cells to external stimuli can be followed over
a period of time by measuring the differences in global
gene expression. Global transcription analysis provides a
new approach to the description of complex biological
phenomena [12-14]; it is also of great use in the field of
cancer biology [15-19].
Networks of interacting proteins can provide researchers
rudimentary understanding in cellular mechanisms;
therefore, it is possible to understand the cellular func-
tions of Reishi polysaccharide (F3) through their linkages
to characterized receptors. In broader terms, networks of
gene linkages offer a new view on the meaning of F3 func-
tion, and in time should provide us with a more in-depth
understanding of the function of cells [20]. Traditionally,
protein-polysaccharide interactions have been studied
individually by genetic, biochemical or biophysical tech-
niques. However, the speed of which new proteins are
being discovered or predicted has created a need for high-
throughput interaction-detection methods. Conse-
quently, in the last two years, more efficient methods have
been introduced to tackle the problem globally, and in
turn provide researchers with vast amount of interaction
data [21]. In silico (computational) interaction predictions
derived from gene context analysis (gene fusion [22,23],
gene neighborhood [24,25] and gene co-occurrences or
phylogenetic profiles [26,27]) and chip-based analysis
have been reported [28]. However, little knowledge has
been obtained with regard to protein-polysaccharide
interactions. Identifying protein-F3 interactions and con-
structing anti-cancer pathways are quite important in
revealing the molecular mechanisms involved in anti-can-
cer activities.
Tumor necrosis factor-related apoptosis inducing ligand
(TRAIL, also called Apo2L or TNFSF10) is capable of
inducing apoptosis in cancer cells but not in normal cells
[29]. It is possible that certain connection to the Apo2L
signaling pathway contributes to anti-tumor activities.
Apo2L seems to be a potential candidate for anti-cancer
drug [30]. The four cellular receptors binding to Apo2L are
death receptor 4 (DR4, also called TRAIL-R1), death recep-
tor 5 (DR5, also called Apo2, TRAIL-R2, TRICK 2,
TNFRSF10B or Killer), decoy receptor 1 (DcR1 or TRAIL-
R3) and decoy receptor 2 (DcR2 or TRAIL-R4) [31-33].
Death receptors belonging to the tumor necrosis factor
(TNF) receptor gene family are defined by cysteine-rich
extracellular domains [34,35]. Signals induced by these
ligand-receptor interactions serve the function of activat-
ing or inducing cell death by apoptosis.
In this study, we intend to find out whether F3 has similar
interactions with death receptors that stimulate apoptosis
pathways in leukemia cells. To study how leukemia cells
are conditioned by F3, we carried out a dynamic analysis
of gene expression in THP-1 cells, a monocytic leukemia
cell line, with F3 treatment at different time points. In this
article, we used oligonucleotide microarray and real-time
quantitative PCR to detect dynamic gene expression pro-
files; and through bioinformatics approach, we also con-
structed a gene network. Finally, we illustrated possible
molecular regulations of Ganoderma lucidum polysaccha-
rides in human monocytic leukemia cells.
Results and discussion
G. lucidum has been used for long time to modulate
immune system and to prevent or treat various human
diseases [36]. The biologically active compounds origi-
nally isolated and purified from G. lucidum were identi-
fied as polysaccharides, and the main fraction was
designated as F3 [11]. Although the anti-tumor activity of
G. lucidum associated with polysaccharides was well-
established in vitro and in vivo, detailed mechanisms of
how they work still await to be elucidated [36]. Under-
standing how polysaccharides (F3) stimulate anti-tumor
effects in THP-1 cells is quite important. From gene
expression to the construction of gene network, our
results contribute to the understanding of the molecular
mechanisms of F3 exertion on THP-1 cells. Two molecular
mechanisms of F3-induced immunomodulation activi-
ties, including TLR4 and TLR2 signal pathways, have been
studied [9,10]. In this study, we explored the gene expres-
sion and gene network induced by F3 in leukemia THP-1
cells, and aimed to reveal pathways critical in F3-induced
anti-cancer activity.
The induction of TNF-α in F3-treated human monocytic 
cells THP-1
Upon the binding of TNF-α to TNFR1, monocytic cells are
triggered to undergo apoptosis. This critical regulatory
process is accomplished by activating the caspase cascade
that results in the degradation of various important cellu-BMC Genomics 2007, 8:411 http://www.biomedcentral.com/1471-2164/8/411
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lar proteins. Previous reports showed that lipopolysaccha-
ride (LPS) could markedly stimulate the cytokine
expression, especially TNF-α  [37]. Compared with the
TNF-α expression in LPS-induced THP-1 cells, we could
estimate the optimal effect concentration of F3. We
treated THP-1 cells with different F3 concentrations (1,
10, 50, 100, 200 μg/mL) and LPS (1 μg/mL) for 24 hours,
and measured their TNF-α expressions. Figure 1 demon-
strates that F3 was dose dependent in the activation of
TNF-α expression. TNF-α expression stimulated by F3 at
100 μg/mL and 200 μg/mL was similar to that of LPS at 1
μg/mL. From these TNF-α expression data, we calculated
the EC50 (50% effect concentration) of F3-induced effec-
tiveness to be around 10 μg/mL. If 70% of TNF-α  is
expressed in F3-induced cells compared to LPS-induced
cells, then 30 μg/mL of F3 is required to achieve the same
effectiveness. For further experiments, we used 30 μg/mL
of F3 to treat THP-1 cells.
Apoptotic effect of F3 on THP-1 cells
After THP-1 cells were treated with F3 (30 μg/mL) for 48
hours, we observed the change of cell morphology under
phase-contrast microscope. Differences in cell morphol-
ogy can be detected between un-treated and F3-treated
THP-1 cells. In Figure 2, representative photos of DAPI-
staining results are shown. Cell shrinkage, one of cell
death characteristics, happened in THP-1 cells after 48
hours treatment with F3 (Figure 2A and 2B). During cell
apoptosis, an early event is the nuclear chromatin conden-
sation, leading to the degradation of genomic DNA. DAPI
nuclear staining was performed to check the apoptotic
changes shown by cell morphology (Figure 2C and 2D).
The percentage of chromatin condensed cells in F3-treated
culture saw a significant increase (Figure 2E). Shrunken
nucleus and apoptotic bodies in DAPI staining were fea-
tures in determining whether cells had undergone apop-
tosis. These results indicated that incubation of THP-1
cells with F3 for 48 hours would lead to cell aggregations
and apoptosis.
Recent studies showed G. lucidum to induce apoptosis in
many cancer cells such as lung cancer cells [38], leukemia
cells [39,40], murine skin carcinoma cells [41], colonic
carcinoma cells [42], prostate cancer cells [6], and breast
Characterization of F3 induced cell death in human THP-1  cells Figure 2
Characterization of F3 induced cell death in human 
THP-1 cells. Phase-contrast microscopy was used to detect 
the morphology of the control (A) and F3-treated THP-1 
cells (B). Cell shrinkage, shape irregularity, and cellular 
detachment were observed in F3-treated cells, but not in the 
control. The control (C) and F3-treated THP-1 cells (D) 
were stained with 4, 6-diamidino- 2-phenylindole (DAPI). (E) 
The percentage of chromatin condensed cells. There was 
apparent difference in cell morphology between the un-
treated and F3-treated THP-1 cells.
The expression of TNF-α in F3- or LPS-induced THP-1 cells Figure 1
The expression of TNF-α in F3- or LPS-induced THP-
1 cells. 105 cells/mL concentrations of THP-1 cells were 
seeded in 96-well microplates and incubated overnight. Then 
the cells (1.25 × 104) were treated with F3 at dosages indi-
cated as 1 μg/mL, 10 μg/mL, 50 μg/mL, 100 μg/mL, 200 μg/
mL, and with LPS at the dose of 1 μg/mL, respectively. The 
same volume of medium was used as control After 24 hours, 
the supernatants were collected and in vitro TNF-α activity 
was determined using Human TNF-α Immunoassay Kit 
(Quantikine®, RD systems). TNF-α expression induced by F3 
(100 μg/mL and 200 μg/mL) is similar to that of LPS (1 μg/
mL). From this TNF-α expression data, we calculated the 
EC50 (50% effect concentration) of F3-induced to be around 
10 μg/mL. The error bars indicate SD from triplicate inde-
pendent experiments.
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cancer cells [43]. In our study, we shared the same results
with other reports, but more specifically in that F3
extracted from G. lucidum could in fact induce apoptosis
of leukemia cells THP-1. In our effort to better understand
the mechanism of this apoptotic effect, we used microar-
ray, a high-throughput technique, to measure the
dynamic gene expression in F3-treated THP-1 cells.
Microarray analysis of overall gene expression in F3-
induced THP-1 cells
In order to identify patterns of gene expression associated
with apoptotic effect in THP-1 cells induced by F3, we per-
formed a transcriptomic analysis on the THP-1 control
and F3-treated or LPS-treated THP-1 cells by oligonucle-
otide microarray. In Figure 3, we observed clear separation
of control (0 and 6 hours) and F3-treated (6 and 24
hours) samples after performing principle component
analysis on the gene expression profiles measured by
microarray experiments. Figure 4 shows the flow chart for
our microarray data analysis. In Figure 5, the intensities of
gene expression of one experiment were plotted on the x
axis and the intensities of the other experiment on the y
axis. A single dot represents one gene as shown in the scat-
ter plots. The upper three scatter plots showed no differ-
ence between the control experiments for 0 hour and 6
hours. These results showed the consistency of our dupli-
cate microarray experiments.
Genes with 2-fold change in gene expressions between
THP-1 control and F3- or LPS-treated THP-1 cells were
selected for mapping significantly disturbed biological
pathways. The pathway of apoptosis induction through
the DR3 and DR4/5 death receptors was observed to be
significant (p < 0.05) in F3-treated THP-1 cells.
Significant biological pathways related to F3-induced 
THP-1 cells
The differentially expressed genes were annotated to spe-
cific biological pathways. For each UniGene ID, we
retrieved its biological pathways from either BioCarta [44]
or KEGG [45] through the existing NCI CGAP gene infor-
mation database [46]. Biological pathways were mapped
and sorted on the order of matching significance using
ArrayXPath [47]. Table 1 shows the significant biological
pathways induced by F3 in THP-1 cells. In this study, four
pathways, including TNFR2 signaling pathway, induction
of apoptosis through DR3 and DR4/5 death receptors, NF-
κB signaling pathway, and toll-like receptor pathway may
be involved in F3-induced cell death. The pathway of
apoptosis induction through DR3 and DR4/5 death recep-
tors was found to be the most significant pathway in F3-
The flow chart for the microarray data analysis Figure 4
The flow chart for the microarray data analysis. We 
used Affymetrix HG-U133A chip GeneChip oligonucleotide 
microarray. Initial data analysis was performed using Affyme-
trix Microarray Suite v5.0 software, setting the scaling of all 
probe sets to a constant value of 500 for each GeneChip. 
Additional data analysis was performed using GeneSpring v 
5.1 (Silicon Genetics Inc., Redwood City, California). Genes 
with a 2-fold change in differential expression between THP-
1 control and F3- or LPS-treated THP-1 cells were selected 
for mapping significantly disturbed biological pathways. The 
pathway of apoptosis induction through the DR3 and DR4/5 
death receptors was shown to be very significant in F3-
treated THP-1 cells. F3–6 h and F3–24 h indicate the F3-
treated THP1 cells after 6 hours and 24 hours, respectively. 
LPS-24 h indicates the LPS-treated THP1 cells after 24 hours. 
C-0 h and C-6 h indicate the control THP1 cells (without any 
treatment) in 0 hour and 6 hours, respectively.
The scatter plot depicting the separation of control (0 and 6  hours) and F3-treated (6 and 24 hours) samples based on the  first two principle components derived from the gene  expression profiles measured by microarray experiments Figure 3
The scatter plot depicting the separation of control (0 and 6 
hours) and F3-treated (6 and 24 hours) samples based on the 
first two principle components derived from the gene 
expression profiles measured by microarray experiments.
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treated THP-1 cells for 6 hours. Detailed gene expression
profiles of these four pathways after F3 or LPS treatments
are shown in Table 2. Our findings implicated that multi-
ple mechanisms may be involved in the anti-tumor effects
of F3 extracted from G. lucidum.
In the pathway of apoptosis induction through DR3 and
DR4/5 death receptors, 9 genes were found to be up-regu-
lated and 2 to be down-regulated among the 27 genes in
F3-treated THP-1 cells after F3 treatment for 6 hours. The
9 up-regulated genes include tumor necrosis factor (lig-
and) superfamily, member 10 (TNFSF10 or TRAIL),
tumor necrosis factor receptor superfamily, member 10b
(TNFRSF10B or DR5), caspase 10, apoptosis-related
cysteine peptidase (CASP10), BH3 interacting domain
death agonist (BID), CASP8 and FADD-like apoptosis reg-
ulator (CFLAR), TNFRSF1A-associated via death domain
(TRADD), nuclear factor of kappa light polypeptide gene
enhancer in B-cells inhibitor, alpha (NFKBIA), nuclear
factor of kappa light polypeptide gene enhancer in B-cells
1 (NFKB1), and caspase 7, apoptosis-related cysteine
peptidase (CASP7); all of these genes are involved in cell
death. Two down-regulated genes were DNA fragmenta-
tion factor, 40kDa, beta polypeptide (caspase-activated
DNase, DFFB) and caspase 6, apoptosis-related cysteine
peptidase (CASP6). CASP6 cleavage by caspase-3
(CASP3), caspase-8 (CASP8) or -10 (CASP10) generates
the two active subunits. In the microarray gene expression
results, CASP3 and CASP8 showed no significant differ-
ence after F3 treatment. However, in our Q-PCR gene
expression results, CASP8 showed a significant up-regu-
lated expression. CASP3 and CASP7 were cleaved into
their active forms after F3 treatment as shown in Figure 6.
In summary, F3 may bind to death receptor 4/5, and acti-
vate downstream apoptosis-related cysteine peptidase
such as CASP8, CASP3 and CASP7, leading to the apopto-
sis of THP-1 cells.
The NF-κB signaling pathway includes 21 genes among
which 6 genes were up-regulated after treatment with F3.
These six genes were TRADD, myeloid differentiation pri-
mary response gene (88) (MYD88), interleukin 1, alpha
(IL1A), interleukin 1, beta (IL1B), NFKBIA and NFKB1.
All of these genes are involved and are crucial in cell
death. IL1B at low concentration induced strong apop-
totic responses as revealed by caspase-8 activation and
DNA fragmentation [48]. MYD88 is an adapter protein
involved in Toll-like receptor and IL-1 receptor signaling
pathways in the innate immune response and acts via
interleukin-1 receptor-associated kinase (IRAK1) and TNF
receptor-associated factor 6 (TRAF6), leading to NF-κB
activation, cytokine secretion and inflammatory
responses. MYD88 can also induce IL-8 transcription and
may be involved in myeloid differentiation. TRADD was
observed to be overexpressed over 25-fold after F3 treat-
ment for 3 hours. TRADD is an adapter protein in the
tumor necrosis factor receptor superfamily, in which
member 1A (TNFRSF1A/TNFR1) specifically associates
with the cytoplasmic domain of activated TNFRSF1A/
TNFR1, mediating its interaction with Fas (TNFRSF6)-
Scatter plot of the gene expressions in the repeated microarray experiments Figure 5
Scatter plot of the gene expressions in the repeated microarray experiments. The filtered probe intensities of gene 
expression of one experiment were plotted on the x axis while the intensities of the other experiment were plotted on the y 
axis. Each gene was represented by a single dot in the scatter plot. The upper three scatter plots showed no difference 
between control experiments for 0 hour and 6 hours. These results showed the consistency in duplicate microarray experi-
ments.BMC Genomics 2007, 8:411 http://www.biomedcentral.com/1471-2164/8/411
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associated via the death domain (FADD) [31]. Overex-
pression of TRADD leads to two major TNF-induced
responses, apoptosis and the activation of NF-κB. NF-κB
is a transcription factor regulating the expressions of a
large number of genes critical in apoptosis regulation. NF-
κB is strongly activated shortly after TNF engagement with
TNFR1, generating a pro-survival signal that must be over-
come in many cell types for TNF to induce apoptosis [31].
Many reports also showed that Apo2L/TRAIL could acti-
vate NF-κB [29,49]. In our results, activation of the NF-κB
signaling pathway caused further THP-1 cell death after F3
treatment.
The TNFR2 signaling pathway includes 17 genes among
which 7 genes were differentially expressed in F3- or LPS-
treated THP-1 cells. All of these seven genes were up-regu-
lated after treatments with F3 or LPS, as shown in Table 2.
TNF binds to two different receptors, TNF receptor 1
(TNFR1) and TNFR2 (TNFRSF1B). TNFR2 is produced by
activating lymphocytes and can be cytotoxic to many
types of tumors and cells. TNFR2 expression is to mediate
the anti-tumor effect of TNF, and NO is necessary for this
process, possibly by inhibiting angiogenesis in the tumor
[50]. Like TNFR2, TNF receptor-associated factor 1
(TRAF1) was also up-regulated in F3- or LPS-treated THP-
Table 1: Significantly Disturbed Pathways of F3/LPS-treated THP-1 Cells
Pathway Identifieda p-value q-value
F3 treatment after 6 hr
Induction of apoptosis through DR3 and DR4/5 Death Receptors 9/32 (37) 0 0.0044
Erythropoietin mediated neuroprotection through NF-kB 5/11 (17) 0.0002 0.0110
F3 treatment after 24 hr
Inhibition of Matrix Metalloproteinases 3/9 (15) 0.0146 0.0265
Induction of apoptosis through DR3 and DR4/5 Death Receptors 6/32 (37) 0.0116 0.0265
IFN alpha signaling pathway 3/9 (25) 0.0146 0.0265
Chaperones modulate interferon Signaling Pathway 4/16 (34) 0.0140 0.0265
NF-kB Signaling Pathway 5/23 (49) 0.0112 0.0265
TNFR2 Signaling Pathway 5/18 (32) 0.0036 0.0265
CD40L Signaling Pathway 4/15 (27) 0.0110 0.0265
Bone Remodelling 4/14 (19) 0.0085 0.0265
B Lymphocyte Cell Surface Molecules 3/9 (10) 0.0146 0.0265
Double Stranded RNA Induced Gene Expression 3/10 (14) 0.0199 0.0321
Antisense Pathway 2/4 (13) 0.0208 0.0321
The information-processing pathway at the IFN-beta enhancer 4/15 (27) 0.0110 0.0440
LPS treatment after 24 hr
B Lymphocyte Cell Surface Molecules 5/9 (10) 0.0006 0.0122
Erythropoietin mediated neuroprotection through NF-kB 5/11 (17) 0.0019 0.0191
Induction of apoptosis through DR3 and DR4/5 Death Receptors 8/32 (37) 0.0071 0.0356
IFN alpha signaling pathway 4/9 (25) 0.0063 0.0356
NFkB activation by Nontypeable Hemophilus influenzae 6/24 (43) 0.0194 0.0481
Toll-Like Receptor Pathway 7/34 (45) 0.0331 0.0481
TNFR2 Signaling Pathway 5/18 (32) 0.0207 0.0481
CD40L Signaling Pathway 4/15 (27) 0.0438 0.0481
IL-10 Anti-inflammatory Signaling Pathway 4/13 (17) 0.0266 0.0481
HIV-I Nef: negative effector of Fas and TNF 10/57 (77) 0.0338 0.0481
Neuropeptides VIP and PACAP inhibit the apoptosis of activated T cells 6/26 (43) 0.0283 0.0481
HIV-1 defeats host-mediated resistance by CEM15 2/3 (5) 0.0243 0.0481
Bone Remodelling 4/14 (19) 0.0346 0.0481
Neutrophil and Its Surface Molecules 3/8 (12) 0.0313 0.0481
Adhesion Molecules on Lymphocyte 3/9 (10) 0.0438 0.0481
GATA3 participate in activating the Th2 cytokine genes expression 5/16 (25) 0.0123 0.0481
Oxidative reactions of the pentose phosphate pathway 2/4 (4) 0.0457 0.0481
NF-kB Signaling Pathway 5/23 (49) 0.0558 0.0487
Chaperones modulate interferon Signaling Pathway 4/16 (34) 0.0543 0.0487
Double Stranded RNA Induced Gene Expression 3/10 (14) 0.0584 0.0487
Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha) 9/54 (64) 0.0574 0.0487
FAS signaling pathway (CD95) 6/30 (34) 0.0536 0.0487
The information-processing pathway at the IFN-beta enhancer 4/15 (27) 0.0438 0.0487
a The ratio between matching genes and total genes in this pathwayBMC Genomics 2007, 8:411 http://www.biomedcentral.com/1471-2164/8/411
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Table 2: Differentially expressed genes of F3- or LPS-induced THP-1 cells using oligonucleotide microarray
Pathway Gene Gene Description Fold Change
F3–6 hr/C F3–24 hr/C LPS-24 hr/C
Induction of apoptosis 
through DR3 and DR4/5 
Death Receptors
TNFSF10* tumor necrosis factor (ligand) superfamily, member 10 9.9 10.1 18.4
TNFRSF10B* tumor necrosis factor receptor superfamily, member 10b 2.1 2.4 2.8
CASP8* caspase 8, apoptosis-related cysteine peptidase 1.3 1.3 1.6
CASP10* caspase 10, apoptosis-related cysteine peptidase 2.9 2.6 2.6
BID BH3 interacting domain death agonist 4.3 1.3 2.2
BCL2* B-cell CLL/lymphoma 2 0.6 0.7 0.7
CYCS cytochrome c, somatic 1.0 0.7 0.8
APAF1 apoptotic peptidase activating factor 0.9 1.0 1.0
CASP9 caspase 9, apoptosis-related cysteine peptidase 0.9 1.0 1.0
CFLAR CASP8 and FADD-like apoptosis regulator 3.1 2.3 4.2
FADD* Fas (TNFRSF6)-associated via death domain 0.8 1.0 0.9
TRADD* TNFRSF1A-associated via death domain 2.1 2.0 1.3
TRAF2 TNF receptor-associated factor 2 1.1 0.9 0.6
RIPK1* receptor (TNFRSF)-interacting serine-threonine kinase 1 1.7 1.1 1.7
MAP3K14 mitogen-activated protein kinase kinase kinase 14 1.6 1.1 1.9
CHUK* conserved helix-loop-helix ubiquitous kinase 0.9 0.8 1.0
NFKBIA* nuclear factor of kappa light polypeptide gene enhancer in B-
cells inhibitor, alpha
12.6 6.6 10.5
NFKB1* nuclear factor of kappa light polypeptide gene enhancer in B-
cells 1 (p105)
5.2 2.2 2.8
BIRC2* baculoviral IAP repeat-containing 2 1.5 1.0 1.7
CASP3* caspase 3, apoptosis-related cysteine peptidase 1.2 1.3 1.3
CASP7* caspase 7, apoptosis-related cysteine peptidase 3.4 2.1 2.7
DFFB DNA fragmentation factor, 40kDa, beta polypeptide (caspase-
activated DNase)
0.4 1.0 0.5
DFFA DNA fragmentation factor, 45kDa, alpha polypeptide 0.8 1.1 0.9
CASP6* caspase 6, apoptosis-related cysteine peptidase 0.5 0.5 0.4
LMNA lamin A/C 1.6 1.6 1.6
GAS2 growth arrest-specific 2 0.8 1.1 1.5
SPTAN1 spectrin, alpha, non-erythrocytic 1 (alpha-fodrin) 1.3 1.3 0.9
NF-kB Signaling Pathway TNFRSF1A tumor necrosis factor receptor superfamily, member 1A 1.6 1.5 1.3
FADD* Fas (TNFRSF6)-associated via death domain 0.8 1.1 0.9
TRADD* TNFRSF1A-associated via death domain 2.1 2.0 1.3
RIPK1* receptor (TNFRSF)-interacting serine-threonine kinase 1 1.7 1.1 1.7
TRAF6 TNF receptor-associated factor 6 1.3 1.1 1.1
TLR4 toll-like receptor 4 1.3 1.2 0.9
IRAK1 interleukin-1 receptor-associated kinase 1 0.6 0.8 0.6
MYD88 myeloid differentiation primary response gene (88) 4.0 2.6 2.7
IL1A interleukin 1, alpha 3.2 1.2 2.4
IL1B interleukin 1, beta 63.2 17.5 53.1
MAP3K7IP1 mitogen-activated protein kinase kinase kinase 7 interacting 
protein 1
0.7 1.0 0.8
MAP3K7 mitogen-activated protein kinase kinase kinase 7 1.1 0.9 0.9
CHUK* conserved helix-loop-helix ubiquitous kinase 0.9 0.8 1.0
MAP3K1 mitogen-activated protein kinase kinase kinase 1 0.8 1.2 1.1
MAP3K14 mitogen-activated protein kinase kinase kinase 14 1.6 1.1 1.9
IKBKB inhibitor of kappa light polypeptide gene enhancer in B-cells, 
kinase beta
0.8 1.0 0.9
IKBKG inhibitor of kappa light polypeptide gene enhancer in B-cells, 
kinase gamma
1.2 1.2 1.2
NFKBIA* nuclear factor of kappa light polypeptide gene enhancer in B-
cells inhibitor, alpha
12.6 6.6 10.5
NFKB1* nuclear factor of kappa light polypeptide gene enhancer in B-
cells 1 (p105)
5.2 2.2 2.8BMC Genomics 2007, 8:411 http://www.biomedcentral.com/1471-2164/8/411
Page 8 of 17
(page number not for citation purposes)
RELA v-rel reticuloendotheliosis viral oncogene homolog A, nuclear 
factor of kappa light polypeptide gene enhancer in B-cells 3, 
p65 (avian)
1.0 1.1 1.1
TNFR2 Signaling 
Pathway
LTA lymphotoxin alpha 1.4 1.7 1.2
TNFRSF1B tumor necrosis factor receptor superfamily, member 1B 4.3 3.5 4.1
RIPK1* receptor (TNFRSF)-interacting serine-threonine kinase 1 1.7 1.1 1.7
TRAF1 TNF receptor-associated factor 1 5.9 4.4 7.9
TRAF2 TNF receptor-associated factor 2 1.1 0.9 0.6
TRAF3 TNF receptor-associated factor 3 1.3 1.1 1.2
TANK TRAF family member-associated NFKB activator 2.3 1.9 2.9
MAP3K14 mitogen-activated protein kinase kinase kinase 14 1.6 1.1 1.9
MAP3K1 mitogen-activated protein kinase kinase kinase 1 0.8 1.1 1.1
DUSP1 dual specificity phosphatase 1 2.7 1.5 4.0
CHUK* conserved helix-loop-helix ubiquitous kinase 0.9 0.8 1.0
IKBKB inhibitor of kappa light polypeptide gene enhancer in B-cells, 
kinase beta
0.8 0.9 0.9
IKBKG inhibitor of kappa light polypeptide gene enhancer in B-cells, 
kinase gamma
1.2 1.2 1.2
IKBKAP inhibitor of kappa light polypeptide gene enhancer in B-cells, 
kinase complex-associated protein
0.9 1.0 0.7
TNFAIP3 tumor necrosis factor, alpha-induced protein 3 12.7 5.4 11.4
NFKBIA* nuclear factor of kappa light polypeptide gene enhancer in B-
cells inhibitor, alpha
12.2 6.6 10.5
NFKB1* nuclear factor of kappa light polypeptide gene enhancer in B-
cells 1 (p105)
5.2 2.2 2.8
Toll-like Receptor 
Pathway
TLR2 toll-like receptor 2 1.2 2.1 2.6
CD14 CD14 antigen ; CD14 antigen 0.5 15.2 16.9
MYD88 myeloid differentiation primary response gene (88) 4.0 2.6 2.7
TLR4 toll-like receptor 4 1.3 1.2 0.9
LY96 lymphocyte antigen 96 0.6 5.3 6.3
TOLLIP toll interacting protein 1.0 1.1 1.2
IRAK1 interleukin-1 receptor-associated kinase 1 0.6 0.8 0.6
TRAF6 TNF receptor-associated factor 6 1.3 1.1 1.1
EIF2AK2 eukaryotic translation initiation factor 2-alpha kinase 2 5.1 4.0 4.5
SITPEC signaling intermediate in Toll pathway, evolutionarily 
conserved
0.8 0.7 0.4
MAP3K1 mitogen-activated protein kinase kinase kinase 1 0.8 1.2 1.1
CHUK* conserved helix-loop-helix ubiquitous kinase 0.9 0.8 1.0
IKBKB inhibitor of kappa light polypeptide gene enhancer in B-cells, 
kinase beta
0.8 1.0 0.9
IKBKG inhibitor of kappa light polypeptide gene enhancer in B-cells, 
kinase gamma
1.2 1.2 1.2
NFKBIA* nuclear factor of kappa light polypeptide gene enhancer in B-
cells inhibitor, alpha
12.6 6.6 10.5
MAP3K7 mitogen-activated protein kinase kinase kinase 7 1.1 0.9 1.0
MAP3K7IP2 mitogen-activated protein kinase kinase kinase 7 interacting 
protein 2
1.6 1.2 1.4
MAP3K7IP1 mitogen-activated protein kinase kinase kinase 7 interacting 
protein 1
0.7 1.0 0.8
MAP2K3 mitogen-activated protein kinase kinase 3 2.2 1.5 1.9
MAP2K6 mitogen-activated protein kinase kinase 6 0.7 1.1 0.8
MAPK14 mitogen-activated protein kinase 14 0.6 0.9 0.8
MAP2K4 mitogen-activated protein kinase kinase 4 0.9 1.0 1.0
MAPK8 mitogen-activated protein kinase 8 2.6 1.2 1.5
JUN v-jun sarcoma virus 17 oncogene homolog (avian) 7.9 1.3 2.6
FOS v-fos FBJ murine osteosarcoma viral oncogene homolog 1.5 2.3 1.8
ELK1 ELK1, member of ETS oncogene family 0.9 1.4 1.5
*These genes have been validated by Q-PCR.
Table 2: Differentially expressed genes of F3- or LPS-induced THP-1 cells using oligonucleotide microarray (Continued)BMC Genomics 2007, 8:411 http://www.biomedcentral.com/1471-2164/8/411
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1 cells. TRAF1 is an adapter protein and signal transducer
that links members of the TNFR family to different signal-
ing pathways by association with the receptor cytoplasmic
domain and kinases. TRAF1 is involved in apoptosis by
mediating the activation of NF-κB and c-Jun N-terminal
kinase (JNK) [51]. TRAF family member-associated NF-κB
activator (TANK) acts as a regulator of TRAF function by
maintaining TRAF in a latent state. Alpha-induced protein
3 (TNFAIP3), a tumor necrosis factor, was induced by
TNF-α and identified as a regulatory component of a puta-
tive cytoplasmic signaling cascade that mediates NF-κB
activation in response to DNA damage [52].
Toll-like receptor pathway was observed to be significant
(p < 0.05 and q < 0.05) in LPS-treated but not in F3-
treated THP-1 cells (Table 1). This pathway includes 27
genes among which six and seven genes were differentially
expressed in F3- and LPS-treated THP-1 cells, respectively.
After F3 treatment for six hours, MYD88, eukaryotic trans-
lation initiation factor 2-alpha kinase 2 (EIF2AK2), NFK-
BLA, mitogen-activated protein kinase kinase 3
(MAP2K3), mitogen-activated protein kinase 8 (MAPK8)
and v-Jun sarcoma virus 17 oncogene homolog (avian)
(JUN) were up-regulated and CD14 antigen (CD14) was
down-regulated. Interestingly, CD14 was up-regulated
after treatments with LPS and F3 for 24 hours. CD14
cooperates with TLR4 to mediate the innate immune
response to LPS and acts via MYD88 and TRAF6, leading
to NF-κB activation, cytokine secretion and the inflamma-
tory response. Lymphocyte antigen 96 (LY96) was up-reg-
ulated after treatment with F3 or LPS for 24 hours. The
downstream signaling pathway used by toll-like receptors
are similar to that used by IL-1 receptors, which is activat-
ing the IL-1 receptor associated kinase (IRAK) through the
MYD88 adaptor protein, and signaling through TRAF-6
and protein kinase cascades to activate NF-κB and Jun
[53]. In conclusion, the expression of these genes in the
toll-like receptor pathway may implicate their associa-
tions with THP-1 apoptosis after F3 or LPS treatment.
Comparisons between oligonucelotide microarray and Q-
PCR results
To further validate our findings from the microarray anal-
ysis, we selected a set of genes known for their involve-
ment in apoptosis through death receptors, and carried
out gene expression studies using Q-PCR. 18 gene expres-
sions related to the death receptor pathway were exam-
ined between F3- or LPS-treated THP-1 cells for 3, 6, 12,
and 24 hours. mRNAs were reverse-transcribed and
amplified through Q-PCR using primers specific for each
gene of interest; the housekeeping gene, GAPDH, was
used as internal control. Each experiment was repeated
three times. The results are shown in Figure 7 and 8. Sig-
nificance analysis of Q-PCR measurements was per-
formed by EDGE software package [54]. There were nine
significantly differential gene expressions in F3-treated
THP-1 cells, including TNFRSF10B, CASP7, CASP6,
TRADD, CASP3, TNFSF12, baculoviral IAP repeat-con-
taining 2 (BIRC2/c-IAP), conserved helix-loop-helix ubiq-
uitous kinase (CHUK/IKKα), and NF-κB (NFKB1);
whereas in LPS-treated THP-1 cells these were TNFRSF12,
CASP7, TNFSF12, CASP6, TRAF2, and NFKB1. Figure 9
shows that nearly all genes are consistent between the
microarray and Q-PCR data.
We compared the 18 gene expressions in the time courses
after F3 or LPS treatments, as shown in Figure 7 and 8. Sta-
tistically significant difference of time-course gene expres-
sion profiles between F3 and LPS treatment was observed
for TRADD, CHUK, TRAF2, BIRC2, TNFSF10, FADD,
CASP3, CASP10, CASP6, BCL2, and NFKB1, while other
genes exhibited similar expression trends. These results
suggest that THP-1 cells have similar but different gene
expression response to F3 and LPS treatments.
Construction of cell death gene networks and possible 
pathways involved in F3-induced THP-1 cell death
Based on our time-course Q-PCR data, we constructed the
cell death gene network in F3-treated THP-1 cells by our
self-developed software tool, BSIP [55]. Assuming that
gene regulatory network follows the S-system mathemati-
cal model [56], we used BSIP to estimate the modeling
parameters, identify the optimized structure, compare the
concordance, and infer a plausible regulatory network.
Moreover, we established the interrelated apoptosis path-
ways initiated by F3 in THP-1 cells using our concurrent
findings, as illustrated in Figure 10. Death receptors,
which belong to tumor necrosis factor (TNF) gene super-
CASP3 and CASP 7 were cleaved into active forms after F3  treatment in THP-1 cells Figure 6
CASP3 and CASP 7 were cleaved into active forms after F3 
treatment in THP-1 cells. After THP-1 cells were treated 
with F3 for 0, 6, 12, 24 hours, we detected proforms and 
active forms of CASP3 and CASP7 using western blotting. 
CASP3 and CASP7 were activated after F3 treatment.
 20 kDa 
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family, are cell surface receptors that transmit apoptosis
signals and play a crucial role in apoptosis and cell sur-
vival. Our characterized death receptors are TNFR1
(tumor necrosis factor receptor-1), TNFR2 (tumor necro-
sis factor receptor-2), and DR4/5 (also called TRAIL-R1/2)
[31]. TNF-α and TNFSF10, also called TRAIL, exhibit an
increase in gene expression in F3-treated THP-1 cells.
When TNF-α binds to TNFR1, adaptor protein TRADD
recruitment follows, and then it interacts with another
death domain-containing molecule FADD, leading to the
subsequent cleavage of pro-caspase-8 [57]. The binding of
TRAIL to DR4/5 also induces the recruitment of FADD
and pro-caspase-8 of auto-proteolytic activation [37].
Interactions between pro-caspase-8 and FADD result in
further activation of caspase-3 and caspase-7, and also the
initiation of apoptosis [58]. In addition to apoptotic sig-
nals, recruitment of TRAF2 through TNFR2 binding TNF-
α activates NF-κB, thus producing anti-apoptotic signals
[59]. TNFR1 also activates anti-apoptotic NF-κB. NF-κB-
dependent activation of TRAF2, RIPK1, and BIRC2 gene
expressions seemed to support this because TRAF2 and
RIP interacting with TRADD prevented caspase-8 activa-
tion, while c-IAPs inhibited caspase-3 and caspase-7 acti-
vation [60]. When NF-κB is activated, IκB is
phosphorylated by protein kinase IKK and this phospho-
rylation serves as a signal for the ubiquitination and deg-
radation of IκB. Free NF-κB dimers are released and
translocated to the nucleus, where they enhance the tran-
scription of target genes. NF-κB activation and IκB degra-
dation prompt cell survival signals and mediate immune
responses [61]. In contract, NF-κB is a transcription factor
that regulates expression of a large number of genes criti-
cal for the regulation of apoptosis, and many reports have
showed that Apo2L/TRAIL can activate NF-κB [29,49]. All
in all, NF-κB activation can promote apoptosis or survival,
depending on the cellular contents [49].
Fold change in time-course gene expression of F3- or LPS-induced THP-1 cells by Q-PCR Figure 7
Fold change in time-course gene expression of F3- or LPS-induced THP-1 cells by Q-PCR. First, THP-1 cells were treated with 
F3 or LPS for different periods of time and were collected at different time points. Total RNA was isolated from cell lines using 
TRIzol reagent. First-strand cDNA synthesis were performed with 5 μg of total RNA in a volume of 20 μl with 1 μl Thermo-
Script™ Reverse Transcriptase (Invitrogen) and 1 μl oligo(dT). Extracted first-strand cDNAs were analyzed using BioRad iCy-
cler iQ Real-Time Detection System with SYBR Green dye (Molecular Probes, Eugene, OR). Software designed for the BioRad 
iCycler will aid in analyzing collected data. mRNA expression of these genes were normalized to RNA content for each sample 
by using GADPH gene products as internal controls. Relative expression was calculated as the ratio of expression from each 
F3-treated THP-1 cells in comparison to untreated THP-1 cells (control). The error bar came from n > 3. The p values indicate 
the statistical significance of different time-course gene expression profiles between F3 and LPS treatment.
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Conclusion
In conclusion, we performed time-course microarray
analysis and Q-PCR assays for measuring gene expression
profiles of F3-treated THP-1 cells. Integrating the expres-
sion data, we applied computational modeling to infer
plausible gene regulatory networks involved in F3-
induced cell death. Our results suggested that F3 might
mimic/induce death receptor ligands such as TNF-α and
TRAIL to initiate signaling via death receptor oligomeriza-
tion, recruitment of specialized adaptor proteins, and the
activation of caspase cascade, followed by cell shrinkage
and apoptosis. This study confirmed microarray analysis
to be a powerful tool for demonstrating gene expressions
related to the efficacy of anti-tumor drugs such as Gano-
derma lucidum polysaccharides, F3, on tumor growth. This
approach opens a different way of elucidating the molec-
ular mechanisms for anti-tumor compounds or drugs in
cancer cells. Information in this study may present a pow-
erful tool for cancer diagnosis and therapy.
Methods
Materials
Crude Reishi extract (prepared via alkaline extraction
(0.1N NaOH), neutralization and ethanol precipitation)
was obtained from Pharmanex Co. (CA, USA). All chemi-
cals and reagents were from Sigma-Aldrich Co., unless
indicated.
Purification of Reishi extract
Crude Reishi powder (obtained from Pharmanex Co.) 6 g
was dissolved in 120 mL of dd water, stirred at 4°C for 1
hour, and centrifuged (1000 rpm) for 1 hour to remove
the insoluble. The resulting solution was concentrated at
40~ 50°C to give a small volume which then was lyophi-
lized to generate 5 g (83%) powder of dark-brown color.
This water soluble residue was stored at -20°C for further
purification.
Isolation of the F3 fraction of Reishi polysaccharide [8]
F3 was isolated from the dark powder of water soluble res-
idue of Reishi polysaccharide. The procedure during chro-
matography was maintained at 4°C in cool room. The 2.1
g sample was dissolved in a small volume of Tris buffer
(pH7.0, 0.1N) containing 0.1% sodium azide, and puri-
fied by gel filtration chromatography using a Sephacryl S-
500 column (95 × 2.6 cm) with 0.1N Tris buffer (pH 7.0)
as the eluent. The flow rate was set at 0.6 mL/min, and 6.0
mL per tube was collected. After the chromatography,
each fraction was subjected to phenol-H2SO4 method to
detect the content of sugar in each tube. Five fractions
were collected (fractions 1–5), F3 fraction was concen-
Fold change in time-course gene expression of F3- or LPS-induced THP-1 cells by Q-PCR Figure 8
Fold change in time-course gene expression of F3- or LPS-induced THP-1 cells by Q-PCR. (continued from Figure 7)
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Comparisons between oligonucelotide microarray and Q-PCR results Figure 9
Comparisons between oligonucelotide microarray and Q-PCR results. (A) THP-1 cells were treated with F3 for 6 
hours (A) and 24 hours (B) and with LPS for 24 hours (C). The gene expressions showed consistent trends between the 
microarray and Q-PCR results. The error bar came from n > 3.
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trated at 40~ 50°C to give a small volume in rotary vapor,
which was dialyzed or purified through G-50 column to
remove excessive salt and sodium azide and was then
lyophilized to give 520 mg (25%) of F3.
THP-1 cell culture and induction of cell death
The monocyctic cell-line THP-1 cells were seeded at an ini-
tial concentration of 105 cells/mL in RPMI 1640 Medium
supplemented with 2 mg/mL sodium bicarbonate
(Atlanta Biologicals, GA, USA), 4.5 mg/mL glucose, 2 mg/
mL HEPES, 1% Antibiotic-antimycotic, 10% serum fetal
bovine. Cells were cultured at 37°C in an incubator with
controlled humidified atmosphere containing 5% CO2.
We detected apoptotic cells by 4,6-diamidino-2-phenylin-
dole (DAPI; Sigma, St. Louis, MO, USA) staining. After
washing with PBS and fixing with 4% paraformaldehyde
for 15 min, the cells were stained with 2 mg/mL DAPI for
20 min. The stained cells were examined under a fluores-
cent microscope and cells were considered to undergo
apoptosis based on the appearance of nuclear fragmenta-
tion.
Detection of TNF-α activity by colorimetric sandwich 
ELISA
The induction agent, lipopolysaccharide (LPS) or F3, was
dissolved in RPMI 1640 Medium at a stock concentration
of 4 mg/mL and 2 mg/mL, respectively; then stored at -
20°C. THP-1 cells with 105 cells/mL concentrations were
seeded in 96-well microplates and incubated overnight.
Then the cells (1.25 × 104) were treated with F3 at the dos-
ages indicated as 1 μg/mL, 10 μg/mL, 50 μg/mL, 100 μg/
mL, 200 μg/mL, and with LPS at the dose of 1 μg/mL,
respectively. The same volume of medium was applied as
control. After 24 hours, the supernatants were collected at
indicated time points by centrifugation at 1200 g for 5
min. In vitro TNF-α activity was determined using Human
TNF-α  Immunoassay Kit (Quantikine®, RD systems)
based on the manual provided. The procedure is briefly
described as follows. Assay Diluent RD1F solution (50 μL)
and 200 μL of sample supernatants, standard and control,
were gently mixed and loaded into individual wells. After
2 hours of incubation at room temperature, each well was
aspirated, washed three times with 400 μL of Wash Buffer,
loaded with 200 μl of secondary antibody solution (TNF-
α Conjugate solution) at room temperature for 1 hour.
The same aspiration and wash procedures were per-
formed; 200 μL of substrate solution was then added to
each well and incubated in darkness at room temperature
for 20 min. The enzymatic reaction was finally terminated
by the addition of 50 μl of Stop Solution. The optical den-
sity was determined using a microplate ELISA reader
(Molecular Devices Corporation, California, USA) set at
450 nm with the correction wavelength at 540 or 570 nm.
The concentration of TNF-α was determined by plotting
the sample reading against the standard curve. All the
measurements were performed in triplicate.
Microarray gene expression analysis
THP-1 cells with 107 cells/mL concentrations were seeded
in 100 mm dish and incubated overnight. After that, cells
were treated with F3 and LPS at a final concentration of 30
μg/mL and 1 μg/mL, respectively. After incubated for 6
and 24 hours, the cell pellets were collected by centrifuga-
tion at 250 g for 5 min, correspondingly. Controlled sam-
ples of un-induced cells were treated in the same way with
the same amount of medium. Total cellular RNA was
extracted from a minimum of 5 × 106 cells with the use of
TRIzol reagent (Invitrogen Life Technologies, Carlsbad,
CA, USA); RNA was additionally purified with phenol-
chloroform-isoamylalcohol (25:24:1). Purity was con-
firmed by spectrophotometry (A260/A280 ratio) and capil-
lary electrophoresis (Agilent 2100 Bioanalyzer, Agilent
Inc, Foster City, CA). RNA processing and hybridization
onto Affymetrix (Santa Clara, CA) HG-U133A GeneChip
oligonucleotide microarray were performed according to
the manufacturer's protocol. Initial data analysis was per-
formed using Affymetrix Microarray Suite v5.0 software,
setting the scaling of all probe sets to a constant value of
500 for each GeneChip. Additional data analysis was per-
formed using GeneSpring v5.1 (Silicon Genetics Inc., Red-
wood City, California). Principle component analysis on
gene expression profiles of control (0 and 6 hours) and
F3-treated (6 and 24 hours) samples were performed
Proposed F3-induced cell death pathways in THP-1 cells Figure 10
Proposed F3-induced cell death pathways in THP-1 
cells. Based on our self-developed software for the recon-
struction of gene networks in addition to literature research, 
we proposed plausible cell death pathways induced by F3 in 
THP-1 cells. F3 may induce death receptor ligands (TNF-α 
and TRAIL) to initiate signaling via receptor oligomerization, 
recruitment of specialized adaptor proteins and activation of 
caspase cascades. Lastly, cell shrinkage and apoptosis occur.BMC Genomics 2007, 8:411 http://www.biomedcentral.com/1471-2164/8/411
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using Cluster 3.0 [62]. Genes with 2-fold change in differ-
ential expression between THP-1 control (combining 0
and 6 hours in total of four arrays) and F3- or LPS-treated
THP-1 cells were selected for further analysis. Based on
fold-change expression, genes that were differentially
expressed between the two repeated microarray experi-
ments were subjected to a scatter-plot analysis.
Functional classification of differentially expressed genes
The differentially expressed genes were classified into
groups based on their annotated functions using the
BGSSJ software tool [63]. BGSSJ is an XML-based Java
application that organizes lists of genes or proteins
according to Gene Ontology database for biological inter-
pretation [64], and organizes information based on
molecular functions, biological processes, and cellular
components for a number of different organisms. For our
transcriptomic data, the UniGene IDs of the differentially
expressed genes were used to input into BGSSJ with a data-
base option of "NCBI + GO".
Biological pathway annotations
The differentially expressed genes were annotated to spe-
cific biological pathways. For each UniGene ID, we
retrieved its biological pathways from either BioCarta [44]
or KEGG [45] through the existing NCI CGAP gene infor-
mation database [46]. Biological pathways were mapped
and sorted on the order of matching significance using the
ArrayXPath web tool [47].
Table 3: Primer sequences in Q-PCR experiments
Gene Name Primer Sequence PCR products
Sense Primer
BCL2-S CGATGTGATGCCTCTGCGAAG 95 bp
BCL2-A GCCATGCTGATGTCTCTGGAATC
BIRC2-S GTTCCAGTTCAGCCTGAGCAG 102 bp
BIRC2-A CCAACACCTCAAGCCACCATC
CASP10-S CACAGTCCACCCACCCTCTC 132 bp
CASP10-A CTTCCTATGTGAGCACCTTCCTTAC
FADD-S ACAGCATCGAGGACAGATACCC 96 bp
FADD-A CCACTGTTGCGTTCTCCTTCTC
TNFRSF10B-S GCACCACGACCAGAAACACAG 124 bp
TNFRSF10B-A CAATCACCGACCTTGACCATCC
TNFRSF12-S TCAGCCAATGTGTCAGCAGTTC 150 bp
TNFRSF12-A CGCAGCCATCGCCATGTTC
TNFSF10-S GCTGAAGCAGATGCAGGACAAG 136 bp
TNFSF10-A CTGACGGAGTTGCCACTTGAC
TNFSF12-S TCAACAGCTCCAGCCCTCTG 146 bp
TNFSF12-A CACACCATCCACCAGCAAGTC
TRADD-S TTTGCTGGCGGACGAGGAG 119 bp
TRADD-A CCGAGCCGCACTTCAGATTTC
CHUK-S GCCATCCACTATGCTGAGGTTG 140 bp
CHUK-A GCACGCTGTTCCAGAGATTCC
NFKB1-S CTCAAAGCAGCAGGAGCAGATC 71 bp
NFKB1-A TCCCAAGAGTCATCCAGGTCATAG
NFKBIA-S AGTGATCCGCCAGGTGAAGG 130 bp
NFKBIA-A ACAGCCAGCTCCCAGAAGTG
RIPK1-S AAGTGGGTGATGAGGGAAGGC 80 bp
RIPK1-A TCGATCCTGGAACACTGGTGG
TRAF2-S AACATTGTCTGCGTCCTGAACC 159 bp
TRAF2-A AGCCATCGCCAGGTCCTTG
Casp3-S ATGGACCACGCAGGAAGGG 68 bp
Casp3-A GGCAGCATCATCCACACATACC
Casp6-S GCCACGCAGATGCCGATTG 139 bp
Casp6-A CCAACCAGGCTGTGACACTTG
Casp7-S GTCTCACCTATCCTGCCCTCAC 114 bp
Casp7-A TTCTTCTCCTGCCTCACTGTCC
Casp8-S GAAAAGCAAACCTCGGGGATAC 113 bp
Casp8-A CCAAGTGTGTTCCATTCCTGTC
GAPDH-S ACACCCACTCCTCCACCTTTG 98 bp
GAPDH-A GCTGTAGCCAAATTCGTTGTCATAC
"S" means sense strand; "A" means anti-sense strand.BMC Genomics 2007, 8:411 http://www.biomedcentral.com/1471-2164/8/411
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Statistical analysis for identification of significantly 
disturbed pathways
The disturbed pathways with statistical significance were
identified based on Fisher's exact test and false discovery
rate. The statistical analysis was performed using ArrayX-
Path.
Primer design
Primers were designed based on the published sequences
in NCBI. We used Beacon Designer [65] to design the
primers. Primers were designed to meet the following
requirements: 75–150 bp in length, 50–60% in CG con-
tent, less than 5 degrees Tm difference between forward
and reverse primers, limited GC repeats, amplicons
between 80–120 bp, and limited dimer and hairpin for-
mation. The designed primers are shown in Table 3.
Quantitative real-time PCR
Gene expression of the genes in death receptor pathway
was determined by RT-PCR. Total RNA were isolated from
cell lines using TRIzol reagent according to the manufac-
turer's protocol. First-strand cDNA synthesis was per-
formed on 5 μg of total RNA in a volume of 20 μl with 1
μl ThermoScript™ Reverse Transcriptase (Invitrogen) and
1 μl oligo(dT). Extracted first-strand cDNAs were analyzed
using a BioRad iCycler iQ Real-Time Detection System
with SYBR Green dye (Molecular Probes, Eugene, OR).
SYBR Green yields a strong fluorescent signal on binding
double-stranded DNA enabling the quantification of gene
expression by measurement of the intensity of the fluores-
cent light. SYBR Green will bind to any PCR product
amplified by primers and is therefore, non-specific and
less accurate than designing specialized probes. Targeted
products were between 100–200 bp. For each experimen-
tal setup, a standard curve was prepared consisting of 5
dilutions of PCR products. Software produced for the Bio-
Rad iCycler will aid in evaluating collected data. mRNA
expression of these genes were normalized to RNA con-
tent for each sample by using GADPH gene products as
internal controls. The relative expression was calculated as
the ratio of expression from each F3-treated THP-1 cells
compared with the control THP-1 cells.
Significance analysis of Q-PCR experiments
Significance analysis of Q-PCR experiments was per-
formed by the EDGE software tool [54,66]. EDGE is based
on Optimal Discovery Procedure, a new method that
finds the optimal rule for calling differentially expressed
genes, and Time Course Methodology.
Western blotting
F3-treated and untreated THP-1 cells were washed with
PBS twice. Cell pellets (1 × 107 cells) were solubilized in
lysis buffer containing 7 M urea, 4% CHAPS, 2M thiourea,
and 0.002% bromophenol blue. Lysates were centrifuged
at 13,200 × g for 30 mins. Proteins were loaded into 10%
SDS-PAGE and transferred onto polyvinylidene difluoride
membranes (Millipore, Bedford, MA) at 150 V for 1.5
hours. After blocking in 5% nonfat milk in PBST contain-
ing 0.05% Tween 20 (Sigma) at room temperature over-
night with gentle rocking, membranes were probed with
antibodies. Primary antibodies involved in this study
include CASP3 (IMGENEX, San Diego, CA) and CASP7
(Upstate, Lake Placid, NY) diluted in 1:200 and 1:300,
respectively. Membranes were incubated with corre-
sponding primary antibody and then incubated with sec-
ondary antibodies (biotinylated anti-mouse IgG-HRP,
1:2000 dilution, Abcam, Cambridge, UK). After incuba-
tion with secondary antibodies, immunoblots were visu-
alized with the ECL detection kit (Amersham Biosciences)
and exposed to X-ray film. β-actin was used as an internal
loading control.
Network construction
Based on the time-course Q-PCR data, we reconstructed a
plausible gene regulatory network in F3-treated THP-1
cells using the BSIP web tool [55]. We developed BSIP to
solve the reverse engineering problems for gene regulatory
network or other biological networks. BSIP is a PHP-based
web server for identification of biological networks using
experimental time-series data obtained from microarray,
Q-PCR, proteomics, or metabolomics measurements.
Based on the S-system modeling formalism,
, where Xi represents the gene
expression level and αj, βj, gij, and hij represent the regula-
tory parameters, an evolutionary optimization method
with data collocation [56] was used to estimate the mod-
eling parameters with the measured time-series data of
gene expression and determine the regulatory network
structure.
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